SynthesisFrontiers in oncology2026
Hepatoid adenocarcinoma of the lung with normal serum alpha-fetoprotein managed with thoracic radiotherapy followed by tislelizumab plus lenvatinib: a case report and systematic review.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatoid adenocarcinoma of the lung (HAL) is a rare pulmonary malignancy. This study presents a case of HAL with normal serum alpha-fetoprotein (AFP) and systematically reviews previously reported cases. Methods: The clinicopathologic and molecular characteristics, treatment, and outcome of the index case were described. For the systematic review, PubMed, Embase, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang Data were searched from January 2000 to 4 July 2026. Patient-level data were extracted from eligible reports. Methodological quality was assessed using the Joanna Briggs Institute checklists. Overall survival (OS) was evaluated using Kaplan-Meier analysis and Cox regression. Results: The index patient was diagnosed with HAL, with normal serum AFP and no established actionable driver alterations identified. After thoracic radiotherapy followed by tislelizumab plus lenvatinib, the patient achieved a partial response and remained progression-free for nearly 10 months. The systematic review included 91 studies comprising 109 patients. The median age was 63 years. Men accounted for 91% of patients, and 86% of patients with available data had a smoking history. Stage III-IV disease was reported in 88/106 patients (83%). Serum AFP was elevated in 49/81 patients (60%), thyroid transcription factor 1 (TTF-1) was negative in 56/87 patients (64%), and genomic alterations were identified in 19/53 molecularly tested patients (36%). The median OS among 83 patients with available survival data was 14 months (95% CI, 9-19 months). Stage IV disease was associated with shorter OS in multivariable analysis (HR, 2.47; 95% CI, 1.18-5.19; P = 0.017). These findings should be interpreted in light of potential publication, selection, and reporting biases. Conclusion: HAL was most frequently reported in older men with a history of smoking. Most patients had stage III-IV disease at diagnosis, and OS was generally short. Clinical stage was associated with OS, whereas the prognostic value of serum AFP remained uncertain. No standard treatment has been established. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420261440722.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.